« Back to Record
Citation APA

Donskov, F., Motzer, R. R., Voog, E., Hovey, E., Grüllich, C., Nott, L. L., Cuff, K., Gil, T., Jensen, N. V., Chevreau, C., Negrier, S., Depenbusch, R., Bergmann, L., Cornelio, I., Champsaur, A., Escudier, B., Pal, S., Powles, T. B. T., & Choueiri, T. T. (2020). Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. European journal of cancer, 126, 1-10. doi:10.1016/j.ejca.2019.10.032


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/298823

Donskov, F., Motzer, R. R., Voog, E., Hovey, E., Grüllich, C., Nott, L. L., Cuff, K., Gil, T., Jensen, N. V., Chevreau, C., Negrier, S., Depenbusch, R., Bergmann, L., Cornelio, I., Champsaur, A., Escudier, B., Pal, S., Powles, T. B. T., & Choueiri, T. T. (2020). Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. European journal of cancer, 126, 1-10. doi:10.1016/j.ejca.2019.10.032